Palbociclib: a new partner for cetuximab?

Affiliations

¹ Section of Hematology/Oncology, Department of Medicine and Comprehensive Cancer Center, The University of Chicago, Chicago, IL 60637, USA.
² Section of Hematology/Oncology, Department of Medicine and Comprehensive Cancer Center, The University of Chicago, Chicago, IL 60637, USA. Electronic address: evokes@medicine.bsd.uchicago.edu.

Comment

Garth W Strohbehn et al. Lancet Oncol. 2019 Sep.

. 2019 Sep;20(9):1195-1196.

doi: 10.1016/S1470-2045(19)30484-X. Epub 2019 Jul 24.

¹ Section of Hematology/Oncology, Department of Medicine and Comprehensive Cancer Center, The University of Chicago, Chicago, IL 60637, USA.
² Section of Hematology/Oncology, Department of Medicine and Comprehensive Cancer Center, The University of Chicago, Chicago, IL 60637, USA. Electronic address: evokes@medicine.bsd.uchicago.edu.

No abstract available

Comment on

Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial.
Adkins D, Ley J, Neupane P, Worden F, Sacco AG, Palka K, Grilley-Olson JE, Maggiore R, Salama NN, Trinkaus K, Van Tine BA, Steuer CE, Saba NF, Oppelt P. Adkins D, et al. Lancet Oncol. 2019 Sep;20(9):1295-1305. doi: 10.1016/S1470-2045(19)30405-X. Epub 2019 Jul 24. Lancet Oncol. 2019. PMID: 31351869 Clinical Trial.